Consortium Associated Partners will complement the Consortium Beneficiaries and the TOLERATE research training programme, by enrolling the TOLERATE fellows into a doctoral programme, providing training and secondments opportunities.
Werfen (Llica d Amunt, Spain) is a worldwide leader in specialized diagnostics in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity.
Our Hemostasis product line is comprised of in vitro diagnostic systems, reagents, information management and service, used to diagnose and guide treatment of thrombotic and bleeding disorders.
Marta Palicio is the R&D Innovation Director of the Werfen Technology Center in Barcelona, center of excellence in Immunoassay Development. Her role is to drive innovation in the R&D activities, scouting new products and technologies of interest for the company, exploring collaboration opportunities, and boosting internal innovation.
Marta has more than twenty years of experience in biomedical research and biotechnology. After a PhD, she worked in Genset, a French pharmacogenomics company, as program coordinator. Afterwards, she worked as International Affairs Manager at Eurasanté, an agency specialized in the economic development of the health sector in the Nord-Pas de Calais Region (France). Between 2006 and 2012, she worked as Scientific Business Developer at Oryzon, a Spanish biomarker and therapeutic target discovery company. She joined Werfen in 2012.
Werfen will bring to the consortium its expertise in trial development by providing secondments for students as agreed in the project. In addition, Marta Palicio will be able to provide training on the development of diagnostic tests from their conception in the laboratory to their launch on the market and other matters such as intellectual property management.
R&D Innovation Director, Werfen Technology Center
The European Hematology Association (Den Haag, Netherlands) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. EHA brings together all relevant stakeholders to promote excellence in patient care through education, research, and advocacy.
One core mission of EHA is to support the career development of researchers in hematology, and the collaboration with TOLERATE is instrumental in achieving this goal. In TOLERATE, EHA will contribute as Associate partner to the dissemination activities (through EHA channels, the EHA Congress and other initiatives) and providing network opportunities with different stakeholders involved with EHA (for example, patient representatives).
Francesco Cerisoli, PhD, Head of Research and Mentoring at the European Hematology Association Executive Office is representing EHA in TOLERATE.
Francesco Cerisoli, PhD
Head of Research and Mentoring, EHA Executive Office
Immudex ApS (Copenhagen, Denmark) is a pioneering life science company spearheading the global adoption of precision immune monitoring. Since 2009, Immudex strives to provide researchers worldwide with reliable tools to monitor the cellular immune response accurately.
Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. Based on their proprietary Dextramer® and dCODE® technologies Immudex provide reagents and kits allowing researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells.
Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies. Research, development, and commercial activities are headquartered outside Copenhagen in Virum, Denmark.
Bjarke Endel Hansen, PhD in Immunology, is a Senior scientist with 20+ years of research experience in immunology, with a special focus on development of reagents and assays to immune monitor specific T cells, B cells and CAR T cells within infectious and autoimmune diseases.
Liselotte Brix, PhD in immunology and biotechnology. CSO at Immudex. 20+ years experienced in research, development and marketing of technology within immunology, immune monitoring and diagnostics; cofounder of Immudex.
From left, back row: Kevin Lenogue, Katrine Frederiksen, Mille Jul Petersen, Kivin Jacobsen. Second row: Bjarke Endel Hansen, Thomas Holberg Blicher, Amalie Skak Schøller. Front row: Trine Louise Sjöberg, Liselotte Brix, Maria Rigét Mejlhart, Tobias Skovgaard Mortensen
INN-ACTA (Siena, Italy) is a SME specialized in managing European Commission funded projects with many years of experience from several European Framework Programmes, including collaborative projects in Health Programmes, RIA, CSA, IMI projects, as well as Marie Curie Actions.
INN-ACTA’s expertise ranges from grants management (administrative tasks, compilation of high-quality reports, communications to EC) to communication activities (e.g., printed materials, flyers, brochures, newsletters, project websites, videos), training activities, organization of project meetings, conferences, workshops and project events. INN-ACTA’s support is provided to EU project coordinators and consortia, as partner of the consortium, partner organization or associated partner.
Laura Maccari, PhD, Grant manager for INN-ACTA has scientific and managerial background gained from >15 years’ experience in biotech companies. She is a specialist in the management of EC funded grants. In TOLERATE, she will be responsible for supporting the coordinator and the consortium in the management of administrative tasks of the project and communication activities.
She will be joined by Natascia Cannella - specialist in administration, financing, project management, Simona Farnetani - event manager supporting meeting organization, and the IT team to develop the project website.
Universidad Autonoma de Barcelona, located in Bellaterra near Barcelona, Spain, is one of the major public universities in Spain. Currently, UAB offers more than 100 bachelor’s degrees, covering a wide range of fields in humanities and arts, social sciences, health sciences, technology and physical sciences and more than 140 master’s degrees, as well as 8 Erasmus Mundus master's degrees. Finally, it runs 68 doctoral programs and an average of 522 PhD dissertations are defended per year.
Since its foundation in 1968, UAB has been acknowledged for its excellence in promoting quality in teaching and in attracting international talent. In the 2020 edition of the Times Higher Education World University Rankings, UAB placed second among Spanish universities. UAB is also the hub of UAB Sphere, a knowledge ecosystem that includes research centres, most of them situated on UAB’s campus and also integrates local businesses, authorities and the largest hospital network in Catalonia.
UAB will enrol DC6 into the Doctoral Programme.
Academisch Medisch Centrum bij de Universiteit van Amsterdam (Amsterdam, Netherlands) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. Over 7000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching.
The AMC complex houses the University Hospital and the Faculty of Medicine of University of Amsterdam as well as the Emma Children’s Hospital, the Netherlands Institute for Neuroscience, the Medical Department of the Royal Tropical Institute and the Amsterdam Institute for Global Health and Development.
AMC will enrol DC5 into the Doctoral Programme.
Universiteit van Amsterdam (Amsterdam, Netherlands) is the largest university in the Netherlands, in terms of student numbers and choice of study programmes and one of the largest research universities in Europe.
UvA hosts over 30,000 students (of whom 5,000 students are international), 3,000 PhD researchers, 6,000 staff and 100 different nationalities and has an annual budget of more than 600 million euros.
UvA ranks among Europe's 20 best universities and consistently scores in the top 100 of global rankings including the Times Higher Education World University Rankings, QS World University Rankings, the Academic Ranking of World Universities (Shanghai Ranking) and the CWTS Leiden Ranking. The UvA hosts 3,000 PhD candidates and awards on average 550 PhD degrees each year.
UvA is the PhD degree awarding entity for AMC-based DC5.
The University of Antwerp (Antwerp, Belgium) is a young and dynamic Belgian university. It is characterized by high standards in education, internationally competitive research and entrepreneurial approach.
The University's roots go back to 1852. The University of Antwerp has about 21,100 students, which makes it the third largest university in Flanders. Education and research are closely connected.
UA will enrol DC4 in its Doctoral School.
The Medical School of Medicine of Sorbonne-Université (formerly Medical University Pierre and Marie Curie, Paris, France), is a Training and Research Unit (Unité de Formation et de Recherche –UFR- in French) created in 1968. It is one of the six Medical Schools of Paris region. It is associated to the hospital group called “Groupe Hospitalier Universitaire (GHU) Sorbonne – Université” of Assistance Publique – Hôpitaux de Paris (AP-HP).
The Medical School of Medicine of SU will enrol the DC1 into its Doctoral Programme.
The Technische Universität Dresden (Dresden, Germany) is one of the largest “Technische Universitäten” in Germany and one of the leading and most dynamic universities in Germany.
As a full-curriculum university with 17 faculties in five schools it offers a broad variety of 124 disciplines and covers a wide research spectrum. Its focuses Health Sciences, Biomedicine & Bioengineering, Information Technology & Microelectronics, Smart Materials & Structures, Energy, Mobility & Environment as well as Culture & Societal Change are considered exemplary in Germany and throughout Europe. Since 2012, TUD has been one of the “Universities of Excellence”.
TUD will enrol DC3 in its Doctoral Programme.